Death domain containing receptors

Details Death domain containing receptors Death domain containing receptors

2008-04-15

2008-04-15

O'Hara, Eileen B. (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S139100, C424S141100, C424S143100, C530S387100, C530S387300, C530S387900, C530S388100, C530S391100, C530S391300, C530S389100, C530S388220, C530S350000, C435S326000, C435S331000, C435S334000

Reexamination Certificate

active

07357927

ABSTRACT:
The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5349052 (1994-09-01), Delgado et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5464938 (1995-11-01), Smith et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 6469144 (2002-10-01), Ashkenazi
patent: 2260754 (1998-01-01), None
patent: 0 401 384 (1990-12-01), None
patent: 0 506 477 (1992-09-01), None
patent: 0 585 939 (1994-03-01), None
patent: WO 98/06842 (1988-02-01), None
patent: WO 94/09137 (1994-04-01), None
patent: WO 94/13808 (1994-06-01), None
patent: WO 95/06058 (1995-03-01), None
patent: WO 95/10540 (1995-04-01), None
patent: WO 96/14328 (1996-05-01), None
patent: WO 96/26736 (1996-09-01), None
patent: WO 96/34095 (1996-10-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 97/33899 (1997-09-01), None
patent: WO 97/34911 (1997-09-01), None
patent: WO 97/37020 (1997-09-01), None
patent: WO 98/02543 (1998-01-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/07880 (1998-02-01), None
patent: WO 98/14565 (1998-04-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/30694 (1998-07-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/49305 (1998-11-01), None
patent: WO 98/56892 (1998-12-01), None
patent: WO 00/08139 (2000-02-01), None
Vukicevic et al., 1996, PNAS USA 93:9021-9026).
U.S. Appl. No. 09/912,293, Rosen et al., not published, pp. 1-75 (p. 1 & 2 partially redacted); portion of Table 2; and SEQ ID Nos. 23953, 27198 and 221987.
U.S. Appl. No. 09/912,292, Rosen et al., not published, pp. 1-75 (pp. 1 & 2 partially redacted); portion of Table 2; and SEQ ID Nos. 42495 and 42567.
Adams, M.D. et al., “Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project,”Science 252:1651-1656 (1991).
Adams, M.D. et al., “Sequence identification of 2,375 humam brain genes,”Nature 355:632-634 (1992).
Aggarwal, B.B. and K. Natarajan, “Tumor necrosis factors: Developments during the last decade,”Eur. Cytokine Netw. 7(2):93-124 (Apr.-Jun. 1996).
Altschul, S.F. et al., “Basic Local Alignment Search Tool,”J. Mol. Biol. 215:403-410 (1990).
Ansari, A.A. et al., “HLA-D gene studies in relation to immune responsiveness to a grass allergen Lol p III,”Immunogenet. 33:24-32 (1991).
Arend et al. “Binding of II-1α, IL-1β, and IL-1 Receptor Antagonist by Soluble IL-1 Receptors and Lveles of Soluble IL-1 Receptors in Synovial Fluids,” J. Immunol. 153:4766-4774 (1994).
Armitage, R.J., “Tumor necrosis factor receptor superfamily members and their ligands,”Curr. Opin. Immunol 6:407-413 (Jun. 1994).
Ashkenazi, A. et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991).
Baens, M. et al., “Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived frmo a Somatic Cell Hybrid,”Genomics 16:214-218 (1993).
Baker, E. et al., “Chromosomal location of the human tumor necrosis factor receptor genes,”Cytogenet. Cell Genet. 57:117-118 (1991).
Banchereau, J. et al., “Long-Term Human B Cell Lines Dependent on Interleukin-4 and Antibody to CD40,”Science 251:70-72 (1991).
Banner, D.W. et al., “Crystal Structure of the Soluble Human 55 kd Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation,”Cell 73:431-445 (1993).
Baum, P.R. et al., “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34,”EMBO J. 13(17):3992-4001 (Sep. 1994).
Beutler, B., and Cerami, A., “Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator,”Ann. Rev. Biochem. 57:505-518 (1988).
Birkeland, M.L. et al., “Gene structure and chromosomal localization of the mouse homologue of rat OX40 protein,”Eur. J. Immunol. 25:926-930 (Apr. 1995).
Bodmer, J.-L. et al., “TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95),”Immunity 6:79-88 (Jan. 1997).
Boldin, M.P. et al., “A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain,”J. Biol. Chem. 270:7795-7798 (Apr. 1995).
Boldin, M.P. et al., “Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death,”Cell 85:803-815 (Jun. 1996).
Caliceti, P., et al., “Biopharmaceutical Properties of Uricase Conjugated to Neutral and Amphiphilic Polymers,”Bioconjugate Chem. 10:638-646 (Aug. 1999).
Camerini, D. et al., “The T Cell Activation Antigen CD27 Is a Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Gene Family,”J. Immunol. 147(9):3165-3169 (1991).
Chinnaiyan, A.M. et al., “FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis,”Cell 81:505-512 (May 1995).
Chinnaiyan, A.M. et al., “FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis,”J. Biol. Chem. 271:4961-4965 (Mar. 1996).
Chinnaiyan, A.M. et al., “Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95,”Science 274:990-992 (Nov. 1996).
Corti, A. et al., “Identification of an Epitope of Tumor Necrosis Factor (TNF)-Receptor Type 1 (p55) Recognized by a TNF-α-Antagonist Monoclonal Antibody,”Lymphokine Cytokine Res. 13:183-190 (Jun. 1994).
Delgado, C., et al., “The Uses and Properties of PEG-Linked Proteins,”Clin. Rev. Ther. Drug Carrier Systems 9:249-304 (1992).
Deng, B., et al., “An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis,”Blood 92:1981-1988 (Sep. 1998).
Dürkop, H. et al., “Molecular Cloning and Expression of a New Member of the Nerve Growth Factor Receptor Family That Is Characteristic for Hodgkin's Disease,”Cell 68:421-427 (1992).
Engelmann, H. et al., “Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine,”J. Biol. Chem. 265(3):1531-1536 (1990).
Feinstein, E. et al., “The death domain: a module shared by proteins with diverse cellular functions,”TIBS 20:342-344 (Sep. 1995).
Fiers, W., “Tumor necrosis factor,”FEBS Lett. 285:199-212 (1991).
Francis, G.E. et al., “PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques,”.Intl. J. Hematol. 68:1-18 (Jul. 1998).
Fu, M.L.X. et al., “Characterization of anti-peptide antibodies directed against an extracellular immunogenic epitope on the human α1-adrenergic receptor,”Clin. Exp. Immunol. 97:146-151 (Jul. 1994).
Gillette-Ferguson, I. and C.L. Sidman, “A specific intercellular pathway to apoptotic cell death is defective in the mature peripheral T cells of autoimmunelprandgldmice,”Eur. J. Immunol. 24:1181-1185 (May 1994).
Goeddel, D.V. et al., “Tumor Necrosis Factors: Ge

Affiliated with

Also associated with

Rating

Death domain containing receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Death domain containing receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Death domain containing receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2747841